qualigen therapeutics stock forecast

Post-Market 0.07 (3.32%) Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. Should I buy or sell QLGN? $1.51 $7.50. Read market forecasts, QLGN financials, economic background and market news 1 of the analysts rate the stock as a âBuyâ. Analysts have given the companyâs stock an average 52-week price target of $9.5, forecast between a low of $9.5 and high of $9.5. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, â¦ How has Qualigen Therapeutics's share price performed over time and what events caused price changes? AT CLOSE 4:00 PM EDT 03/19/21. CARLSBAD, Calif., Dec. 22, 2020-- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier, Dec. 22, 2020-- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a Qualigen Therapeutics Forecast Models Qualigen Therapeutics time-series forecasting models is one of many Qualigen Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Analyst recommendations provided by FactSet shows that the consensus forecast for Qualigen Therapeutics Inc. (QLGN) is a âBuyâ. ET by Tonya Garcia. Aug. 25, 2020 at 9:28 a.m. A Form 4 filing filed with the SEC on Wednesday, December 30 â¦ Qualigen Therapeutics (QLGN): Q1 GAAP EPS of -$0.13 beats by $0.01.Revenue of $1.9M (+111.1% Y/Y) beats by $0.7M.As of March 31, 2021, Qualigen Therapeutics had $21.9 million of cash and. QLGN 2.11 0.01 (0.48%). 50-Day Range. Latest Share Price and Events Stable Share Price : QLGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Check out QLGN short interest and earnings date annual report by comparing QLGN insider trading history and institutional ownership breakdown to maximise your investment return on the stock market. SmoothJB May 15. Sector Healthcare RiskRating. Only 15.40% of the stock of Qualigen Therapeutics is held by insiders. Do NOT follow this link! $1.53 $2.69. Revenue growth over the past 12 months for Qualigen Therapeutics Inc comes in at 172.66%, a number that bests 96.4% of the US stocks we're tracking. Qualigen Therapeutics last posted its quarterly earnings results on May 14th, 2021. Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. Furthermore, Qualigen Therapeutics Inc. (QLGN)âs beta value is -0.84, and its average true range (ATR) is 0.14. Qualigen Therapeutics stock rated buy with $10 price target at Alliance Global Partners after merger with Ritter Pharmaceuticals. Qualigen Therapeutics Inc (QLGN:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. SA Breaking News. Earnings results for Qualigen Therapeutics , Analyst Opinion on Qualigen Therapeutics , Earnings and Valuation of (NASDAQ:QLGN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, View More Wall street estimates Earnings report Qualigen Therapeutics (NASDAQ:QLGN) Insider buying vs selling Have Qualigen Therapeutics Inc insiders been buying or selling? Qualigen Therapeutics Inc Stock Ownership Add to Watchlist. Qualigen Therapeutics, Inc. (Nasdaq: QLGN) 2042 Corte del Nogal Suite B. Carlsbad, CA 92011 Plus a detailed analysis of the biotechnology specialist's financials and forecast. Qualigen Therapeutics stock price prediction is an act of determining the future value of Qualigen Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Qualigen Therapeutics stock future price could yield a significant profit. Get instant access to a free live streaming chart of the Qualigen Therapeutics Inc Stock. Dec-22-20 09:00AM : Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook. Thinking about investing in Qualigen Therapeutics because of the upcoming earnings date annual report or stock price forecast? Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, â¦ Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock. View QLGN's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. ... 'Broker forecast' and 'Recent trades' provided by MoneyAM. Dec-18-20 03:07PM : Qualigen Therapeutics, Inc. 52-Week Range. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, â¦ A Form 4 filing filed with the SEC on Wednesday, December 30 â¦ In the medium term (3months), QLGN's stock price should outperform the â¦ Get a real-time Qualigen Therapeutics (QLGN) stock price quote with breaking news, financials, statistics, charts and more. CARLSBAD, Calif., Dec. 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier, Chairman, Chief Executive Officer and President, has issued a letter to Qualigen's stockholders.The full text is as follows: Qualigen Therapeutics has generated $0.00 earnings per share over the last year. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Stock screener for investors and traders, financial visualizations. $2.22 $2.30. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a âOverweightâ. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook. Our methodology considers analysis of the company's financial situation and how it has traded recently. Stockhouse.com use cookies on this site. As of 2021 June 12, Saturday â¦ During the day the stock fluctuated 7.32% from a day low at $2.05 to a day high of $2.20. Webull offers Qualigen Therapeutics Inc (QLGN) historical stock prices, in-depth market analysis, NASDAQ: QLGN real-time stock quote data, in-depth charts, and a â¦ World Indexes. Speculative. Qualigen Therapeutics Inc stock is lower by -21.90% over the last 12 months.InvestorsObserverâs proprietary ranking system, gives QLGN stock a score of 5 out of a possible 100.. That rank is mainly influenced by a fundamental score of 0. CMTX - Thu Oct 8, 8:00AM CDT. $3.03 USD. Share . SEC Filings (Institutional Ownership Changes) for Qualigen Therapeutics (NASDAQ:QLGN) 6.52% of Qualigen Therapeutics stock is owned by institutions. Qualigen Therapeutics Inc. (QLGN) Analyst Forecasts. Looking at the companyâs year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28%. The company report on December 22, 2020 that Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook.. Get the hottest stocks to trade every day before the market opens 100% free. Qualigen Therapeutics Inc (NASDAQ: QLGN) was trading 2% higher from the previous closing price. $2.01 -0.1 -4.3% Last Trade - 18/06/21. Overview Forecast Earnings Dividend Ownership. Find the buy signals and the stock forecast here! This is 2.14% more than the trading day before Thursday, 27th May 2021. December 22, 2020 - 9:00 am. Find the latest Qualigen Therapeutics, Inc. (QLGN) stock quote, history, news and other vital information to help you with your stock trading and investing. Get a real-time Qualigen Therapeutics (QLGN) stock price quote with breaking news, financials, statistics, charts and more. The Qualigen Therapeutics Inc. stock price fell by -2.33% on the last day (Tuesday, 15th Jun 2021) from $2.15 to $2.10. QLGN's rank also includes a long-term technical score of 0. Qualigen Therapeutics Inc. [NASDAQ: QLGN] loss -1.45% or -0.05 points to close at $3.40 with a heavy trading volume of 927609 shares. December 22, 2020. Further, Qualigen Therapeutics, Inc. (QLGN) has a beta value of -0.82, and an average true range (ATR) of 0.14. Investors can use this forecasting interface to forecast Qualigen Therapeutics historical stock prices and determine the direction of Qualigen Therapeutics's future trends based on various well-known forecasting models. Qualigen Therapeutics announces $12M direct offering, stock -8%. Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update. Cookies are used to offer you a better browsing experience and to analyze our traffic. The 2021 estimates are for Qualigen Therapeutics, Inc. earnings to increase by 71.1%, but the outlook for the next 5-year period is at 0% per year. Our comprehensive analysis of fundamental and technical factors gives QLGN a rank of 5. The latest Qualigen Therapeutics Inc USD0.001 share price. Qualigen Therapeutics Stock Forecast, Price & News $2.23-0.01 (-0.45 %) (As of 06/14/2021 11:02 AM ET) Add. Qualigen Therapeutics net worth as of June 04, 2021 is $0.06B . Qualigen Therapeutics Inc : QLGN. The price has fallen in 6 of the last 10 days, but is still up by 9.95% over the past 2 weeks. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. History; â¦ View Qualigen Therapeutics Inc price, streaming chart and supplemental info. Price target in 14 days: 2.438 USD. Qualigen Therapeutics Inc (7R9B:STU) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. The Companyâs stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. QLGN - Qualigen Therapeutics Inc Share Price. In-depth view of key statistics and finances for QUALIGEN THERAPEUTICS, INC. (QLGN) on MSN Money. QLGN : 1.7800 (-1.11%) Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference GlobeNewswire - Mon Mar 8, 7:30AM CST. Find the latest Earnings Report Date for Qualigen Therapeutics, Inc. Common Stock (QLGN) at Nasdaq.com. QLGN Stock Analysis - [Full Report] Free Signup: Advanced stock screener. This price target is based on 1 analysts offering 12 month price targets for Qualigen Therapeutics in the last 3 months. The expected earnings per share for the stock is $0. Insiders buying/selling: Qualigen Therapeutics (NASDAQ:QLGN) In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock. QLGN Earnings. However, solely looking at the historical price movement is â¦ Our Qualigen Therapeutics Inc (QLGN) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts. Qualigen Therapeutics Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The stock has a 52-week high of $30.75 and low of $3.71. Today's Range. Stock Podcast. Qualigen Therapeutics Inc NASDAQ Updated Jun 16, 2021 11:40 PM. Analysts covering Qualigen Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of â¦ and has now fallen 3 days in a row. Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. QLGN rank of 5 means that it ranks below 95% of stocks. QLGN : 3.42 (+1.48%) Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China PR Newswire - PRF - Thu Oct 8, 8:00AM CDT. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Qualigen Therapeutics Inc have a median target of 9.50, with a high estimate of 9.50 and a low estimate of 9.50. Common stock begins trading today on NASDAQ under the ticker QLGN Company raises $4 million in a private placement. 12/16 15:14. Scan for strong stocks. Crypto Currencies. Institutional Buying and Selling by Quarter QLGN Stock Summary. Qualigen Therapeutics Inc (NASDAQ: QLGN) shares were trading higher on Tuesday. Never miss â¦ Qualigen Therapeutics Stock Forecast, QLGN stock price prediction. Interactive chart of historical net worth (market cap) for Qualigen Therapeutics (QLGN) over the last 10 years. Qualigen Therapeutics 's earnings in 2021 is -$23,218,993.On average, 1 Wall Street analysts forecast QLGN's earnings for 2022 to be $-18,164,827, with the lowest QLGN earnings forecast at $-18,164,827, and the highest QLGN earnings forecast at $-18,164,827. We explain how and compare the best share dealing platforms. Despite being -0.21% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 13 when the QLGN stock price touched $5.08-6 or saw a rise of 6.89%. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.30 million. The median estimate represents a +361.17% increase from the last price of 2.06. Commodities. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Time-series forecasting models ae â¦ For QLGN, its debt to operating expenses ratio is greater than that reported by just 5.37% of US equities we're observing. Qualigen Therapeutics Inc (QLGN) Is it time to buy? Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. QLGN | Complete Qualigen Therapeutics Inc. stock news by MarketWatch. Qualigen Therapeutics does not have a long track record of dividend growth. What this means: Qualigen Therapeutics Inc (QLGN) gets a very poor rank from InvestorsObserver. QLGN stock â¦ Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook. CMTX - Mon Mar 8, 7:30AM CST. Qualigen Therapeutics has such a small amount of debt that we'll set it aside, and focus on the US$24m in cash it held at December 2020. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Investors can use this forecasting interface to forecast Qualigen Therapeutics historical stock prices and determine the direction of Qualigen Therapeutics's future trends based on various well-known forecasting models. Volume1,192 shs. The reported ($0.21) earnings per share for the quarter. ... Get pre-market outlookâ¦ During the day the stock fluctuated 3.54% from a day low at $1.87 to a day high of $1.94. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Qualigen Therapeutics Inc have a median target of 9.50, with a high estimate of 9.50 and a low estimate of 9.50. QLGN stock forecast Our latest prediction for Qualigen Therapeutics Inc's stock price was made on the April 20, 2021 when the stock price was at 1.81$.. THE TECHNICAL ANALYST Is it time to buy QLGN? Qualigen Therapeutics, Inc. (QLGN) estimates and forecasts. Close price at the end of the last trading day (Friday, 28th May 2021) of the QLGN stock was $1.91. â¦ Qualigen Therapeutics Inc stock is down -77.05% over the last 12 months.InvestorsObserverâs proprietary ranking system, gives QLGN stock a score of 0 out of a possible 100.. That rank is influenced by a short-term technical score of 0. About the Qualigen Therapeutics, Inc. stock forecast. Compare. However, solely looking at the historical price movement is usually misleading. By continuing to use our service, you agree to our use of cookies. Find real-time QLGN - Qualigen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. QLGN Stock Forecast - Is QLGN a buy or sell? The median estimate represents a +402.65% increase from the last price of 1.89. Shares in Qualigen Therapeutics Inc are currently priced at $3.33. Find real-time QLGN - Qualigen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Qualigen Therapeutics Slides 11% On $12 Million Securities Placement To Single Investor. Ever wondered how to buy stock in Qualigen Therapeutics, Inc? About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for 20 years. Insider Buys Qualigen Therapeutics Stock. CARLSBAD, Calif., Dec. 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. , a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious... | June 18, 2021 Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook. At that level they are trading at 0.203% discount to the analyst consensus target price of 0.00. Announces Closing of â¦ Find real-time AGE - AgeX Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSââ¢. View the latest Qualigen Therapeutics Inc. (QLGN) stock price, news, historical charts, analyst ratings and financial information from WSJ. In the last year, its â¦ More About Us Qualigen Therapeutics Inc (NASDAQ: QLGN) was trading 2% higher from the previous closing price. Common stock begins trading today on NASDAQ under the ticker QLGN Company raises $4 million in a private placement. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. CARLSBAD, Calif., Dec. 22, 2020 /PRNewswire/ â Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier, Chairman, Chief Executive Officer and President, has issued a letter to Qualigenâs stockholders.The full text is as follows: Benzinga. Qualigen Therapeutics Inc (NASDAQ:QLGN) I think this stock will post a sharp rally from current levels following the earnings report on Friday after-hours. The companyâs stock has been forecasted to trade at an average price of $9.50 over the course of the next 52 weeks, with a low of $9.50 and a high of $9.50. A high-level overview of Qualigen Therapeutics, Inc. (QLGN) stock. The latest earnings per stock, revenues and financial reports for Qualigen Therapeutics Inc (QLGN). In the short term (2weeks), QLGN's stock price should outperform the market by 7.98%.During that period the price should oscillate between -11.22% and +27.11%.. ... Analyst Forecasts. QLGN | Qualigen Therapeutics Inc. Stock Price & News - WSJ. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Find out now with a free analysis on Qualigen Therapeutics. QLGN Stock Forecast. The average price target represents a -100.00% upside from the last price of $2.15. CARLSBAD, Calif., Dec. 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier, Chairman, Chief Executive Officer and President, has issued a letter to Qualigen's stockholders.The full text is as follows: Qualigen Therapeutics, Inc. (NASDAQ:QLGN) trade information. Our Approach Qualigen is a biotechnology company focused on the development and commercialization of therapeutic products for the treatment of cancer and viral diseases, as well as expansion of its flagship FastPack® diagnostic platform. Qualigen Therapeutics Inc Stock Forecast and Price Prognosis Data for 2021 . See Qualigen Therapeutics, Inc. (QLGN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Date Price Open High Low Vol Change ER; Jun 7, 2021: 2.2600: 2.1100 Click here to see how you can learn while you earn. Qualigen Therapeutics Inc (NASDAQ: QLGN) was trading 2% higher from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, December 30 showed that Kruger Kurt H bought 4,000 shares at an average price of $2.94. PR Newswire. Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.

Concrete Dumbbells Weight, Aground Demo Walkthrough, Attract Money With Salt And Rosemary, Letter To My Younger Self Quotes, Princeton Soccer Id Camp 2021, Highwaymen Paintings Signatures, Campus Heights Athens Ohio Resident Portal, Motorcycle Accident Ny 2021, Ctb Vs Cs Dream11 Prediction Today Match, Dominica Ambassador To Malaysia,